The estimated Net Worth of Karen Jean Ferrante is at least $78.1 mil dollars as of 20 May 2024. Karen Ferrante owns over 4,500 units of Unum Therapeutics stock worth over $10,575 and over the last 11 years he sold UMRX stock worth over $0. In addition, he makes $67,482 as Independent Director at Unum Therapeutics.
Karen has made over 1 trades of the Unum Therapeutics stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 4,500 units of UMRX stock worth $10,575 on 20 May 2024.
The largest trade he's ever made was exercising 4,500 units of Unum Therapeutics stock on 20 May 2024 worth over $10,575. On average, Karen trades about 150 units every 0 days since 2014. As of 20 May 2024 he still owns at least 4,500 units of Unum Therapeutics stock.
You can see the complete history of Karen Ferrante stock trades at the bottom of the page.
Dr. Karen Jean Ferrante M.D. serves as Independent Director of the Company. Dr. Ferrante has served as a member of our board of directors since February 2018. Dr. Ferrante is the former Chief Medical Officer and Head of Research and Development of Tokai Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, where she developed treatments for prostate cancer and other hormonally driven diseases between April 2014 and August 2016. From 2007 to July 2013, Dr. Ferrante held senior positions at Millennium Pharmaceuticals, Inc. and its parent company, Takeda Pharmaceutical Company Limited, including Chief Medical Officer and most recently as Oncology Therapeutic Area Head and Cambridge USA Site Head from May 2013 to July 2013. Dr. Ferrante previously held positions of increasing responsibility at Pfizer Global Research and Development and Bristol-Myers Squibb. Dr. Ferrante serves on the board of directors of Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), MacroGenics, Inc. (Nasdaq: MGNX), and Hutchinson China MediTech Limited (Nasdaq: HDM). Dr. Ferrante also served as a director of Baxalta Inc., a publicly traded global biopharmaceutical company from July 2015 until its acquisition by Shire Pharmaceuticals in June 2016. She holds an M.D. from Georgetown University and a B.S. in chemistry and biology from Providence College.
As the Independent Director of Unum Therapeutics, the total compensation of Karen Ferrante at Unum Therapeutics is $67,482. There are no executives at Unum Therapeutics getting paid more.
Karen Ferrante is 62, he's been the Independent Director of Unum Therapeutics since 2018. There are 1 older and 6 younger executives at Unum Therapeutics. The oldest executive at Unum Therapeutics, Inc. is Arlene Morris, 68, who is the Independent Director.
Karen's mailing address filed with the SEC is 9704 MEDICAL CENTER DRIVE, , ROCKVILLE, MD, 20850.
Over the last 6 years, insiders at Unum Therapeutics have traded over $0 worth of Unum Therapeutics stock and bought 1,283,156 units worth $11,122,392 . The most active insiders traders include Llc Fmr, Liam Ratcliffe, eBruce Booth. On average, Unum Therapeutics executives and independent directors trade stock every 72 days with the average trade being worth of $286,216. The most recent stock trade was executed by Healthcare Capital Partners... on 14 August 2020, trading 451,000 units of UMRX stock currently worth $1,136,520.
Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.
Unum Therapeutics executives and other stock owners filed with the SEC include: